GlaxoSmithKline R&D Under Scrutiny In Bid For Fresh Funding
It's crunch time for GlaxoSmithKline PLC's 38 biotech-like R&D units, which are competing for further funding as they reach the end of their first three-year investment cycle.
You may also be interested in...
GSK's various thwarted efforts to boost productivity through R&D revamps begs the question whether big pharma should be trying to do in-house discovery and early development at all.
News and notes from the fourth and final day of the 2014 J.P. Morgan Healthcare Conference, including highlights from Furiex Pharmaceuticals’ late-stage pipeline, GSK’s latest DPU, newly public Intrexon, and angel-backed KemPharm.
GSK transforms DPU in Shanghai into TCM discovery unit that will consist of a small number of select scientists with both Western drug discovery experience and TCM knowledge.